Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

NCT04410445 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT04410445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04410445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Lead sponsor
Nektar Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
July 27, 2020
Completion date
September 22, 2022
Enrollment
765 (actual)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma (skin), melanoma stage iii, melanoma stage iv